Ledipasvir-Sofosbuvir: Interferon-/Ribavirin-Free Regimen for Chronic Hepatitis C Virus Infection

Annals of Pharmacotherapy

Volumn 49, Issue 3, 2015, Pages 343-350

  Smith, Michael A ^a   Chan, Juliana ^b,c   Mohammad, Rima A ^d,e  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

hepatitis C virus; ledipasvir; sofosbuvir

Indexed keywords

ABACAVIR; ANTACID AGENT; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTIMYCOBACTERIAL AGENT; ATAZANAVIR PLUS RITONAVIR; CYCLOSPORIN; DARUNAVIR PLUS RITONAVIR; DIGOXIN; DRUG METABOLITE; EFAVIRENZ; EMTRICITABINE; GS 331007; HYPERICUM PERFORATUM EXTRACT; LAMIVUDINE; LEDIPASVIR PLUS SOFOSBUVIR; ORAL CONTRACEPTIVE AGENT; PEGINTERFERON; PROTON PUMP INHIBITOR; RALTEGRAVIR; RIBAVIRIN; RILPIVIRINE; RITONAVIR PLUS TIPRANAVIR; ROSUVASTATIN; SIMEPREVIR; TACROLIMUS; TENOFOVIR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; INTERFERON; LEDIPASVIR; SOFOSBUVIR; URIDINE PHOSPHATE;

ACUTE CHOLECYSTITIS; AREA UNDER THE CURVE; CELLULITIS; CONVULSION; DIARRHEA; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; GASTROENTERITIS; HAND FRACTURE; HEADACHE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INSOMNIA; INTERVERTEBRAL DISK HERNIA; LIVER CIRRHOSIS; NAUSEA; NONHUMAN; PELVIC ORGAN PROLAPSE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; REVIEW; SPONDYLOLISTHESIS; SUSTAINED VIROLOGICAL RESPONSE; THORAX PAIN; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; UPPER GASTROINTESTINAL BLEEDING; WOUND INFECTION; ADULT; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM;

ADULT; ANIMALS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; FLUORENES; GENOTYPE; HEADACHE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; NAUSEA; RIBAVIRIN; SOFOSBUVIR; URIDINE MONOPHOSPHATE;

EID: 84923841742     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014563952     Document Type: Review

References (47)

1. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.MMWR Recomm Rep. 2012;61 (RR-4): 1-32
2. Rose L,Bias TE,Mathias CB,Trooskin SB,Fong JJ.Sofosbuvir: a nucleotide NS5B inhibitor for the treatment of chronic hepatitis C infection.Ann Pharmacother. 2014;48:1019-1029
3. Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/. Accessed November 29, 2014.
4. Lohmann V.Hepatitis C virus RNA replication.Curr Top Microbiol Immunol. 2013;369:167-198
5. Belema M,Lopez OD,Bender JA, et al.Discovery and development of hepatitis C virus NS5A replication complex inhibitors.J Med Chem. 2014;57:1643-1672
6. Link JO,Taylor JG,Xu L, et al.Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection.J Med Chem. 2014;57:2033-2046
7. Wong KA,Worth A,Martin R, et al.Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885.Antimicrob Agents Chemother. 2013;57:6333-6340
8. Lawitz EJ,Gruener D,Hill JM, et al.A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.J Hepatol. 2012;57:24-31
9. Link JO,Bannister R,Beilke L, et al.Nonclinical profile and phase I results in healthy volunteers of the novel and potent HCV NS5A inhibitor GS-5885.Poster presented at: 61st Annual Meeting of the American Association for the Study of Liver Diseases 2010; Boston, MA;.
10. Foster City, CA: Gilead Sciences, Inc; 2014:
11. Kirby B,Li H,Kearney B,Mathias A.Population pharmacokinetic analysis of ledipasvir (GS-5885) in healthy and hepatitis C virus-infected subjects.Abstract presented at: 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; Washington, DC;.
12. Mogalian E,Mathias A,Yang C, et al.The pharmacokinetics of ledipasvir, an HCV specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment [abstract].Hepatology (Baltimore, Md). 2014;60:1145A-1146A
13. Department of Health and Human Services. Management of hepatitis C: 2002 National Institutes of Health Consensus Conference Statement. http://consensus.nih.gov/2002/2002-hepatitisc2002116html.htm. Accessed November 29, 2014.
14. Chen J,Florian J,Carter W, et al.Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies.Gastroenterology. 2013;144:1450-5.e2
15. Guidance for industry chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm225333.pdf. Accessed November 29, 2014.
16. Bernstein DE,Mangia A,Brau N, et al.Concordance between SVR4, SVR12 and SVR24 in genotype 1 HCV-infected patients who received all oral fixed-dose combination ledipasvir/sofosbuvir with or without ribavirin in phase 3 clinical trials [abstract].Hepatology (Baltimore, Md). 2014;60:1142A-1143A
17. Lawitz E,Poordad FF,Pang PS, et al.Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.Lancet. 2014;383:515-523
18. Afdhal N,Zeuzem S,Kwo P, et al.Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.N Engl J Med. 2014;370:1889-1898
19. Kowdley KV,Gordon SC,Reddy KR, et al.Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.N Engl J Med. 2014;370:1879-1888
20. Afdhal N,Reddy KR,Nelson DR, et al.Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.N Engl J Med. 2014;370:1483-1493
21. Gordon SC,Fried MW,Kwo P, et al.No differences in efficacy of fixed-dose combination ledipasvir/sofosbuvir in patients according to fibrosis stage development determined by liver biopsy or laboratory biomarker in phase 3 clinical trials [abstract].Hepatology (Baltimore, Md). 2014;60:1149A-1150A
22. Bourliere M,Sulkowski M,Omata M, et al.An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin [abstract].Hepatology (Baltimore, Md). 2014;60:239A
23. Mizokami M,Takehara T,Yokosuka O, et al.100% SVR4 in Japanese patients with chronic genotype 1 hepatitis C virus infection receiving ledipasvir/sofosbuvir fixed dose combination for 12 weeks: results from a multicenter phase 3 study [abstract].Hepatology (Baltimore, Md). 2014;60:1130A
24. Gilead Sciences. Ledipasvir/sofosbuvir fixed-dose combination plus ribavirin in subjects with chronic HCV with advanced liver disease or post-liver transplant. http://clinicaltrial.gov/ct2/show/NCT02010255?term=ledipasvir&rank=13. Accessed November 29, 2014.
25. Gilead Sciences. Safety and efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) for 12 or 24 weeks in kidney transplant recipients with chronic HCV infection. http://clinicaltrial.gov/ct2/show/NCT02251717?term=ledipasvir&rank=9. Accessed November 29, 2014.
26. O’Leary JG,Burton JR,Helmke SM, et al.Early improvement in HepQuant (HQ)-SHUNT function test during treatment with ledipasvir/sofosbuvir in liver transplant recipients with allograft fibrosis or cirrhosis and patients with decompensated cirrhosis who have not undergone transplantation [abstract].Hepatology (Baltimore, Md). 2014;60:1134A
27. Osinusi A,Townsend K,Nelson A, et al.O14 Use of sofosbuvir/ledipasvir fixed dose combination for treatment of HCV genotype-1 in patients coinfected with HIV [abstract].J Hepatol. 2014;60 (1): S7
28. Townsend K,Osinusi A,Nelson A, et al.High efficacy of sofosbuvir/ledipasvir for the treatment of HCV genotype 1 in patients coinfected with HIV on or off antiretroviral therapy: results from the NIAID ERADICATE trial [abstract].Hepatology (Baltimore, Md). 2014;60:240A
29. Gane EJ,Hyland RH,An D, et al.O6 Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience [abstract].J Hepatol. 2014;60 (1): S3-S4
30. Flamm SJ,Everson GT,Charlton M, et al.Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study [abstract].Hepatology (Baltimore, Md). 2014;60:320A-321A
31. Gilead Sciences. Efficacy and safety of ledipasvir/sofosbuvir fixed-dose combination in treatment-naïve and treatment-experienced subjects with chronic genotype 4 or 5 HCV infection. http://clinicaltrial.gov/ct2/show/NCT02081079?-term=ledipasvir&rank=16. Accessed November 29, 2014.
32. Gane EJ,Stedman CA,Hyland RH, et al.Once daily sofosbuvir/ledipasivr fixed dose combination with or without ribavirin: the ELECTRON trial [abstract].Hepatology (Baltimore, Md). 2013;58:243A
33. Kapoor R,Kohli A,Sidharthan S, et al.All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial [abstract].Hepatology (Baltimore, Md). 2014;60:321A
34. Gilead Sciences. Safety and efficacy of ledipasvir/sofosbuvir fixed dose combination in adolescents and children with chronic HCV-infection. http://clinicaltrial.gov/ct2/show/NCT-02249182?term=ledipasvir&rank=6. Accessed November 29, 2014.
35. Osinusi A,Marti M,Townsend K, et al.O11 Retreatment of relapsers to sofosbuvir/ribavirin with sofosbuvir/ledipasvir: complete and rapid virologic suppression by week 4 [abstract].J Hepatol. 2014;60:S5-S6
36. Wyles DL,Pockros PJ,Yang C, et al.Retreatment of patients who failed prior sofobuvir-based regimens with all oral fixed-dose combination ledipasvir/sofosbuvir plus ribavirin for 12 weeks [abstract].Hepatology (Baltimore, Md). 2014;60:317A-318A
37. Chung RT,Lauer GM,Stamm LM, et al.Ledipasvir/sofosbuvir is safe and effective in nosocomially infected patients with advanced age and significant cardiac co-morbidities [abstract].Hepatology (Baltimore, Md). 2014;60:1158A
38. Jacobson IM,Kwo P,Kowdley KV, et al.Virologic response rates to all oral fixed-dose combination ledipasvir/sofosbuvir regimens are similar in patients with and without traditional negative predictive factors in phase 3 clinical trials [abstract].Hepatology (Baltimore, Md). 2014;60:1141A-1142A
39. German P,Pang P,Fang L,Chung D,Mathias A.Drug-drug interaction profile of the fixed-dose combination tablet ledipasvir/sofosbuvir [abstract].Hepatology (Baltimore, Md). 2014;60:1162A
40. German P,Moorehead L,Pang P,Vimal M,Mathias A.Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects.J Clin Pharmacol. 2014;54:1290-1298
41. Kitrinos KM,Wyles DL,Dvory-Sobol H, et al.Evaluation of the resistance profile of ledipasvir (LDV), a nonstructural protein 5A (NS5A) inhibitor, in genotype (GT) 1 chronically infected HCV subjects treated with LDV-containing regimens without sofosbuvir (SOF) [abstract].Hepatology (Baltimore, Md). 2014;60:1143A-1144A
42. Sarrazin C,Dvory-Sobol H,Svarovskaia E, et al.Baseline and post-baseline resistance analyses of phase 2/3 studies of ledipasvir/sofosbuvir plus/minus RBV [abstract].Hepatology (Baltimore, Md). 2014;60:1128A
43. PollackA. Harvoni, a hepatitis C drug from Gilead, wins FDA approval. http://mobile.nytimes.com/2014/10/11/business/harvoni-a-hepatitis-c-drug-from-gilead-wins-fda-approval.html?_r=2&referrer=. Accessed November 29, 2014.
44. LondeixP. New treatments for hepatitis C virus: strategies for achieving universal access. http://www.hepcoalition.org/IMG/pdf/daas_strategies_for_achieving_universal_access_en.pdf. Accessed November 29, 2014.
45. Gordon SC,Ahmed A,Saab S,Younossi Z.Evaluation of the long-term health outcomes of ledipasvir/sofosbuvir (LDV/SOF) and sofosbuvir-based regimens for patients with chronic hepatitis C (CHC) and liver cirrhosis across genotypes 1 to 4 (GT 1-4): results form a decision-analytic markov model [abstract].Hepatology (Baltimore, Md). 2014;60:1040A-1041A
46. Younossi Z,Saab S,Ahmed A,Gordon SC.A decision-analytic markov model to evaluate the health outcomes of ledipasvir/sofosbuvir (LDV/SOF) for patients with chronic hepatitis C (HCV) genotype 1 (GT1) infection [abstract].Hepatology (Baltimore, Md). 2014;60:1043A
47. Ahmed A,Gordon SC,Saab S,Younossi Z.Evaluation of the health outcomes for ledipasvir/sofosbuvir in early vs. delayed treatment according to fibrosis stage of patients with chronic hepatitis C virus (HCV) genotype 1 infection: results from a decision-analytic Markov model [abstract].Hepatology (Baltimore, Md). 2014;60:1041A